Magnetic sphincter augmentation for gastroesophageal reflux disease: review of clinical studies

2018 ◽  
Vol 70 (3) ◽  
pp. 323-330 ◽  
Author(s):  
Emanuele Asti ◽  
Alberto Aiolfi ◽  
Veronica Lazzari ◽  
Andrea Sironi ◽  
Matteo Porta ◽  
...  
2018 ◽  
Vol 28 (10) ◽  
pp. 3080-3086 ◽  
Author(s):  
John P. Kuckelman ◽  
Cody J. Phillips ◽  
Michael J. Derickson ◽  
Byron J. Faler ◽  
Matthew J. Martin

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Davide Ferrari ◽  
Emanuele Asti ◽  
Veronica Lazzari ◽  
Stefano Siboni ◽  
Daniele Bernardi ◽  
...  

2014 ◽  
Vol 80 (10) ◽  
pp. 1034-1038 ◽  
Author(s):  
Jessica L. Reynolds ◽  
Joerg Zehetner ◽  
Nikolai Bildzukewicz ◽  
Namir Katkhouda ◽  
Giovanni Dandekar ◽  
...  

Magnetic sphincter augmentation (MSA) of the gastroesophageal junction with the LINX Reflux Management System is an alternative to fundoplication for gastroesophageal reflux disease (GERD) that was approved by the U.S. Food and Drug Administration (FDA) in March 2012. This is a prospective observational study of all patients who underwent placement of the LINX at two institutions from April 2012 to December 2013 to evaluate our clinical experience with the LINX device after FDA approval. There were no intraoperative complications and only four mild postoperative morbidities: three urinary retentions and one readmission for dehydration. The mean operative time was 60 minutes (range, 31 to 159 minutes) and mean length of stay was 11 hours (range, 5 to 35 hours). GERD health-related quality-of-life scores were available for 83 per cent of patients with a median follow-up of five months (range, 3 to 14 months) and a median score of four (range, 0 to 26). A total of 76.9 per cent of patients were no longer taking proton pump inhibitors. The most common postoperative complaint was dysphagia, which resolved in 79.1 per cent of patients with a median time to resolution of eight weeks. There were eight patients with persistent dysphagia that required balloon dilation with improvement in symptoms. MSA with LINX is a safe and effective alternative to fundoplication for treatment of GERD. The most common postoperative complaint is mild to moderate dysphagia, which usually resolves within 12 weeks.


2017 ◽  
Vol 32 (1) ◽  
pp. 405-412 ◽  
Author(s):  
Heather F. Warren ◽  
Lisa M. Brown ◽  
Matias Mihura ◽  
Alexander S. Farivar ◽  
Ralph W. Aye ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Ming-yu Chen ◽  
Di-yu Huang ◽  
Angela Wu ◽  
Yi-bin Zhu ◽  
He-pan Zhu ◽  
...  

Background. The efficacy of Magnetic Sphincter Augmentation (MSA) and its outcomes for Gastroesophageal Reflux Disease (GERD) are uncertain. Therefore, we aimed to summarize and analyze the efficacy of two treatments for GERD.Methods. The meta-analysis search was performed, using four databases. All studies from 2005 to 2016 were included. Pooled effect was calculated using either the fixed or random effects model.Results. A total of 4 trials included 624 patients and aimed to evaluate the differences in proton-pump inhibitor use, complications, and adverse events. MSA had a shorter operative time (MSA and NF: RR = −18.80, 95% CI: −24.57 to −13.04, andP=0.001) and length of stay (RR = −14.21, 95% CI: −24.18 to −4.23, andP=0.005). Similar proton-pump inhibitor use, complication (P=0.19), and severe dysphagia for dilation were shown in both groups. Although there is no difference between the MSA and NF in the number of adverse events, the incidence of postoperative gas or bloating (RR = 0.71, 95% CI: 0.54–0.94, andP=0.02) showed significantly different results. However, there is no significant difference in ability to belch and ability to vomit.Conclusions. MSA can be recommended as an alternative treatment for GERD according to their short-term studies, especially in main-features of gas-bloating, due to shorter operative time and less complication of gas or bloating.


Sign in / Sign up

Export Citation Format

Share Document